Paysign, Inc. develops and manages tailored payment programs for businesses, consumers, and government entities. Its financial results are most closely linked to two specialized areas: plasma donor compensation and pharmaceutical patient affordability initiatives. Rather than going head-to-head with broad consumer payment networks, the company has established a role in regulated, vertical-specific flows where program management and compliance know-how add value. This overview outlines how the business operates and why participants follow the stock.
Incorporated in Nevada on August 24, 1995, the company operated for years as 3PEA International before shifting focus to its Paysign prepaid card brand. It is based in Henderson, Nevada, and lists on Nasdaq under the ticker PAYS, with Mark R. Newcomer, a co-founder, serving as CEO. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
At its core, Paysign acts as a program manager and processor for prepaid and stored-value programs. It issues and oversees reloadable debit cards, prepaid gift cards, and similar instruments for corporate, healthcare, and government clients. Offerings cover corporate rewards, employee incentives, consumer rebates, travel expenses, donor compensation, clinical trial payments, healthcare reimbursements, and pharmaceutical copay assistance, along with a mobile app, SMS alerts, web portal, and customer service support.
Revenue stems mainly from fees. Plasma programs generate income from cardholder and interchange fees, while pharmaceutical programs draw from management fees, transaction processing fees, interchange fees, and settlement income. Additional streams include load fees and breakage from unredeemed balances.
Growth centers on two verticals. The plasma side supplies donor compensation cards to collection centers, backed by an engagement app that ties into donor management systems. The pharmaceutical side runs copay assistance and reimbursement programs. This dual exposure to life-sciences creates a distinct position compared with broader fintech names such as GDOT (Green Dot) or XYZ (Block).
Market participants follow Paysign due to its focus on recurring, essential payment flows. Plasma donation remains steady and resilient, as donors receive compensation per visit and centers require reliable disbursement. Pharmaceutical affordability programs address ongoing out-of-pocket costs, sustaining demand for copay infrastructure. The model features multi-year contracts, recurring fee revenue, and a scalable platform. Management has highlighted expansion in patient affordability programs and a recent acquisition that strengthened software offerings for the blood and plasma sector. From what I see, these elements underpin the long-term growth story at the intersection of fintech and healthcare.
Paysign encounters notable risks despite its specialized approach. Customer concentration stands out, with a limited number of large pharmaceutical and plasma programs historically accounting for a significant portion of revenue and receivables. Losing a major client could materially affect results. The company also operates in regulated fields covering financial services, healthcare, and pharmaceuticals, so shifts in copay rules, plasma regulations, privacy laws, or network policies could impact its model. Macro factors play a role too, as plasma volumes have responded to labor markets and stimulus, while pharmaceutical activity can vary with drug pricing and benefit design. Competition from larger processors remains a factor for any evaluation of its position. I’m watching this closely as these elements shape the risk profile.
Paysign operates as a focused fintech at the meeting point of payments and healthcare rather than a general consumer payments provider. Its fee-based, contract-driven revenue from plasma donor compensation and pharmaceutical affordability programs creates a distinctive recurring model, yet one closely tied to those two verticals and a handful of large clients. For investors, PAYS provides exposure to a specialized payments platform with growth potential alongside meaningful concentration and regulatory risks.
In my own analysis workflow, Tickeron’s AI Screener has proven useful for quickly filtering securities by technical indicators, fundamentals, volatility, trends, and AI signals. It helps surface ideas that align with specific strategies without manually reviewing thousands of tickers. I find it streamlines the process of identifying setups in sectors like fintech and healthcare payments.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The 10-day moving average for PAYS crossed bearishly below the 50-day moving average on November 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PAYS as a result. In 72 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for PAYS turned negative on October 22, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 34 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.
PAYS moved below its 50-day moving average on November 09, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PAYS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +0.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where PAYS advanced for three days, in 253 of 295 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
PAYS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 189 of 245 cases where PAYS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.
The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 38 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is 45 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. PAYS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.933) is normal, around the industry mean (16.188). P/E Ratio (48.904) is within average values for comparable stocks, (45.064). Projected Growth (PEG Ratio) (1.840) is also within normal values, averaging (3.648). Dividend Yield (0.000) settles around the average of (0.427) among similar stocks. P/S Ratio (7.310) is also within normal values, averaging (103.301).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of payment solutions
Industry ComputerCommunications